NDA 020632 · Abbott
Meridia
Sibutramine Hydrochloride · Oral
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 4, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Nov 22, 1997
Approved uses
4
Original approval plus efficacy supplements
Registered trials
32
10 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 8, 2005 Supplement 21 · Efficacy Other Important Information from FDAPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Feb 16, 2001 Supplement 8 · Efficacy LetterLabel
- Feb 16, 2001 Supplement 11 · Efficacy LetterLabel
- Nov 22, 1997 Original approval · Type 1 - New Molecular Entity Review
3 products under this application
- MERIDIA · SIBUTRAMINE HYDROCHLORIDE 10MG · CAPSULE, ORAL · Discontinued
- MERIDIA · SIBUTRAMINE HYDROCHLORIDE 15MG · CAPSULE, ORAL · Discontinued
- MERIDIA · SIBUTRAMINE HYDROCHLORIDE 5MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Sibutramine" as an intervention, any sponsor and status, largest first.
- A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese PatientsPivotal-lookingCompleted
AbbottIndustry
NCT00234832 · 10,777 participants · Start Jan 2003 · Primary completion Mar 2009
Drug: Sibutramine hydrochloride; Placebo and 1 more · For: Obesity
Sites: North Chicago, Illinois
- A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese SubjectsPivotal-lookingCompleted
Nastech Pharmaceutical Company, Inc.Industry
NCT00537420 · 551 participants · Start Oct 2007 · Primary completion Jul 2008
Drug: Nasal Placebo; Placebo Capsule and 4 more · For: Obesity
Sites: Peoria, Arizona; Phoenix, Arizona; Anaheim, California · 29 sites in all
- A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.Pivotal-lookingCompleted
AbbottIndustry
NCT00261911 · 498 participants · Start Jul 2000
Drug: sibutramine · For: Obesity
- Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00533481 · 497 participants · Start Feb 2004 · Primary completion Dec 2004
Drug: MK0557 · For: Obesity
- Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese SubjectsPivotal-lookingTerminated
AbbottIndustry
NCT00645255 · 466 participants · Start Sep 1998 · Primary completion Jan 2003
Drug: placebo; sibutramine or placebo · For: Obesity; Weight Loss
- Sibutramine to Reduce Weight Gain and Improve Smoking Cessation RatesPivotal-lookingCompleted
University of TennesseeAcademic, hospital or other
NCT00037752 · 436 participants · Start Sep 2002 · Primary completion Aug 2008
Drug: Sibutramine · For: Cardiovascular Diseases; Heart Diseases; Obesity
Sites: Memphis, Tennessee
- LOSS- Louisiana Obese Subjects StudyPivotal-lookingTerminated
Pennington Biomedical Research CenterAcademic, hospital or other
NCT00115063 · 390 participants · Start Jul 2005 · Primary completion Dec 2007
Drug: sibutramine, orlistat, diethylpropion · For: Obesity
Sites: Baton Rouge, Louisiana
- A Weight Loss Study in Overweight Men and WomenPivotal-lookingTerminated
Eli Lilly and CompanyEli Lilly (LLY)
NCT00993421 · 343 participants · Start Oct 2009 · Primary completion Jun 2010
Drug: LY377604; Sibutramine and 4 more · For: Obesity
Sites: Mesa, Arizona; Concord, California; La Jolla, California · 21 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Emerging pharmacotherapies for obesity: A systematic review.
Kokkorakis M, Chakhtoura M, Rhayem C, et al. · Pharmacol Rev 2025 · Systematic Review
- Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Franz MJ, VanWormer JJ, Crain AL, et al. · J Am Diet Assoc 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacotherapy for obesity.
Ioannides-Demos LL, Proietto J, McNeil JJ · Drugs 2005 · Meta-Analysis, Review
- Obesity in adults.
Delaet D, Schauer D · BMJ Clin Evid 2011 · Systematic Review
- Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.
Yang S, Xin S, Ju R, et al. · PLoS One 2025 · Systematic Review, Network Meta-Analysis
- Obesity in adults.
Arterburn D, DeLaet D, Schauer D · BMJ Clin Evid 2008 · Systematic Review
Sponsor: Abbott
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.